Author Archive

The reason there is no generic Daraprim

Much has been written on the controversial price increase of Daraprim. Daraprim treats malaria and another parasitic infection, toxoplasmosis. It was acquired by Turing Pharma from Impax Laboratories and shortly after the price was raised from $13.50 a tablet to $750 a tablet. The led to a quick outcry, followed by a) a defense by Turing of their drug […]

Global biotechnology at SXSW

Are you attending SXSW in March? Do you want to hear more about global biotechnology? BiotechBlog frequent contributor Susan Finston and I have proposed a panel on global biotechnology: FoundingBiopharma in a Hard Place: Is India Ready? I will draw on the Scientific American global biotechnology rankings I have published over the last seven years, distilling trends and […]

Lean, Mean, Startup, Machine

This paper is a final project from the NIH Foundation for Advanced Education in the Sciences course — TECH 566: Biotechnology Management Starting up a company is a risky endeavor. From listening to the FAES 566’s course panel discussions this semester, it is clear that there are many challenges a Chief Executive Officer (CEO) will face […]

Drug Patent Expirations for Jul 16, 2015

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit for more options. DEPODUR (morphine sulfate) Pacira Pharms Inc Patent number: 5,931,809 Expiration Date: Jul 14, 2015 TARGRETIN (bexarotene) Valeant Luxembourg Patent number: 5,780,676 Expiration Date: Jul 14, 2015 FIRAZYR (icatibant […]

Get Your WorldView On: 2015 Scientific American Biotech Scorecard #BIO2015

On Thursday June 18th from 12:30 to 2pm in Room 119B Mike May and I will be going over the seventh edition of Scientific American Worldview. Mike is the editor of Worldview. This is a more intimate session than the Super Session (below), and we will discuss the impetus for developing Worldview as well highlighting […]

Come to my book signing at #BIO2015

I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Thursday June 18th from 10:00 am – 11:30 am. Building Biotechnology is used by dozens of schools, and I am always happy to meet professors, students, and industry professionals who have used the book. Stop by, even if it is just to […]

Kickstarting biotechnology crowdfunding #BIO2015

A quick note from BIO2015. Biotechnology crowdfunding levels pale in comparison to other industries. There are many reasons for this disparity — risk, high capital requirements, and the technical nature of many biotechnology applications. A talk by Wharton”s Steve Sammut, based on research by Roger Younan, revealed that biotechnology applications are absent from the list […]

Yali Friedman named one of the 100 most influential people in biotechnology by Scientific American #BIO2015

Scientific American has released its list of the 100 most influential people in biotechnology. I am honored to be included in this exclusive list and recognized for my thought leadership on the business of biotechnology. For more than a decade I have had the privilege to be an entrepreneur and academic without borders, researching and developing publications in areas […]

Discussing Biotechnology in Emerging Markets at #BIO2015

Join me and an esteemed set of panelists at the opening plenary for the Emerging Opportunities in Global Markets track at BIO2015. I will be participating in a discussion that delves deeply into the policies and factors that foster (or hinder) biotech industry success in markets around the world, where I will be discussing the Scientific American Worldview project. […]

Looking forward to BIO #BIO2015

I am looking forward to this year’s BIO convention, as it returns to Philadelphia. It will be a busy conference. In addition to connecting with colleagues, representing the Journal of Commercial Biotechnology, and this blog, I will also be signing books, giving a talk, and attending the Scientific American Worldview rollout. Highlights: I will be signing […]